ADC Therapeutics (ADCT) Q4 2025 Earnings Call Transcript

ADC Therapeutics reported Q4 2025 net product revenue of $22.3 million, up from $16.4 million a year ago, with full-year revenue of $73.6 million and improved losses of $6.4 million in the quarter and $142.6 million for the year. Management reaffirmed LOTIS-5 top-line data in Q2 2026 and highlighted a cash balance of $261.3 million, supporting runway at least into 2028 after two 2025 PIPE financings totaling $160 million. The company also reiterated a $600 million to $1 billion U.S. peak revenue opportunity if ZYNLONTA expands into earlier-line DLBCL and indolent lymphoma settings.

Analysis

ADCT has transitioned from a binary commercial story to a multi-catalyst de-risking setup, but the market is still likely underpricing how much of the current enterprise value is now tethered to one near-term event: LOTIS-5 readout in Q2 2026. The key second-order effect is that success there does not just expand revenue; it also changes the capital structure math by validating that the company can fund launch-scale commercial spend internally through 2028, reducing the odds of a dilutive raise at a weaker valuation.

The most interesting nuance is competitive positioning. ZYNLONTA is not trying to win solely on raw efficacy versus bispecifics; it is trying to become the “accessible backbone” in a market where complex therapies are capacity constrained and physician friction matters. If the combination data hold, the upside is less about stealing share from a single incumbent and more about unlocking previously untreated patients who are not candidates for CAR-T or high-friction regimens, which is why the addressable market can expand faster than consensus models built on current third-line economics.

The main risk is timing slippage or a PFS result that is good enough for approval but not differentiated enough to justify broad prelaunch enthusiasm. Because the street is already leaning into the long-duration option value, any readout that only confirms modest benefit could compress the multiple even if the stock reaction is initially positive. Over the next 3-6 months, the trade is less about today’s run-rate revenue and more about whether the company can convert its cost reset and balance sheet repair into a credible commercial step-up story.

Contrarian view: the consensus may be overfocusing on the $600M-$1B peak narrative and underestimating the likelihood that only one of the expansion paths really works. The base business is stable but not accelerating, so if LOTIS-5 underwhelms, the market may re-rate ADCT back toward a single-asset, late-stage biotech with a long commercialization lag. Conversely, if LOTIS-5 is strong, the move could be sharp because the current valuation likely does not fully reflect a near-term launch-plus-lifecycle rerate.

Key Decisions for Investors

• Long ADCT into LOTIS-5 Q2 2026 as a catalyst trade, but size it as a defined-risk event position; upside is a rerate on de-risked launch math, downside is sharp compression if PFS is only incremental.
• Buy ADCT calls or call spreads expiring after the Q2 2026 readout; the cleaner payoff is on binary validation of second-line expansion rather than owning common through multiple months of dead time.
• For a pair trade, long ADCT / short a basket of crowded lymphoma winners with heavier consensus ownership; ADCT has more valuation torque if combination data surprise positively, while the shorts face less binary upside.
• If already long common, hedge into the readout with short-dated puts to protect against a PFS miss or weaker-than-expected durability data; the stock is vulnerable because expectations are now tied to a single headline catalyst.
• After LOTIS-5, if the data are positive but not clearly best-in-class, fade strength and wait for the follow-through reset; the better entry may be on a post-event pullback rather than chasing pre-readout optimism.